From the Guidelines
There is no clear evidence that Renuva would specifically improve skin quality in people with Classical Ehlers-Danlos Syndrome (EDS), other forms of EDS, or Joint Hypermobility Syndrome. The provided evidence does not support the use of Renuva for improving skin quality in these conditions, as it primarily focuses on treatments for systemic sclerosis and other related diseases 1. Renuva is designed to replace lost volume in soft tissue, but it does not address the underlying collagen defects that cause skin fragility, hyperextensibility, and poor wound healing in EDS and Joint Hypermobility Syndrome. These connective tissue disorders involve genetic mutations affecting collagen production and structure, particularly Type I, III, and V collagen, which Renuva cannot correct. While Renuva might temporarily improve appearance by adding volume to areas of fat loss, it would not address the fundamental skin quality issues in EDS, such as skin fragility, scarring, or delayed wound healing. Additionally, people with EDS often have complications with procedures and healing, so any injectable treatment should be approached with caution. Before considering Renuva, patients with EDS should consult with both a geneticist who specializes in connective tissue disorders and a dermatologist experienced with EDS to discuss potential risks and realistic expectations. It is essential to prioritize treatments that address the underlying causes of skin issues in EDS and Joint Hypermobility Syndrome, rather than just focusing on cosmetic improvements. The current evidence suggests that treatments like immunosuppressive therapy, physical therapy, and other disease-modifying agents may be more effective in managing skin manifestations in related diseases 1. However, more research is needed to determine the best course of treatment for skin quality issues in EDS and Joint Hypermobility Syndrome. In the meantime, a cautious approach to any injectable treatment, including Renuva, is recommended, and patients should be thoroughly informed about the potential risks and benefits.
From the Research
Skin Quality Improvement with Renuva
There are no direct studies on the effectiveness of Renuva in improving skin quality for individuals with Classical EDS, EDS, or Joint Hyper mobility syndromes.
Available Information on EDS and Joint Hypermobility
- The studies 2, 3, 4, 5, 6 discuss the characteristics, diagnosis, and management of Hypermobile Ehlers-Danlos Syndrome (hEDS) and hypermobility spectrum disorders.
- These conditions are associated with joint hypermobility, skin findings, and joint pains or recurrent dislocations 2, 3, 4.
- The central goals of therapy for hEDS and hypermobility spectrum disorders are managing symptoms, preventing joint injury, and educating patients about their condition 2.
- While the studies provide information on the clinical features and management of EDS and joint hypermobility, they do not specifically address the use of Renuva for skin quality improvement.
Limitations of Current Evidence
- The available studies do not provide direct evidence on the effectiveness of Renuva in improving skin quality for individuals with Classical EDS, EDS, or Joint Hyper mobility syndromes.
- Further research is needed to determine the potential benefits of Renuva for skin quality improvement in these conditions.